EP1363611A4 - Retinoidbehandlung von hepatitis - Google Patents

Retinoidbehandlung von hepatitis

Info

Publication number
EP1363611A4
EP1363611A4 EP02707670A EP02707670A EP1363611A4 EP 1363611 A4 EP1363611 A4 EP 1363611A4 EP 02707670 A EP02707670 A EP 02707670A EP 02707670 A EP02707670 A EP 02707670A EP 1363611 A4 EP1363611 A4 EP 1363611A4
Authority
EP
European Patent Office
Prior art keywords
retinoid
hepatitis therapy
hepatitis
therapy
retinoid hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707670A
Other languages
English (en)
French (fr)
Other versions
EP1363611A1 (de
Inventor
Anthony H Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aronex Pharmaceuticals Inc
Original Assignee
Aronex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aronex Pharmaceuticals Inc filed Critical Aronex Pharmaceuticals Inc
Publication of EP1363611A1 publication Critical patent/EP1363611A1/de
Publication of EP1363611A4 publication Critical patent/EP1363611A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP02707670A 2001-02-02 2002-01-31 Retinoidbehandlung von hepatitis Withdrawn EP1363611A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26597701P 2001-02-02 2001-02-02
US265977P 2001-02-02
PCT/US2002/002996 WO2002066022A1 (en) 2001-02-02 2002-01-31 Retinoid hepatitis therapy

Publications (2)

Publication Number Publication Date
EP1363611A1 EP1363611A1 (de) 2003-11-26
EP1363611A4 true EP1363611A4 (de) 2004-08-11

Family

ID=23012660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707670A Withdrawn EP1363611A4 (de) 2001-02-02 2002-01-31 Retinoidbehandlung von hepatitis

Country Status (4)

Country Link
EP (1) EP1363611A4 (de)
JP (1) JP2004522770A (de)
CA (1) CA2437168A1 (de)
WO (1) WO2002066022A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
DE10305138A1 (de) * 2003-02-07 2004-08-26 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
WO2018054891A1 (en) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
WO2002015920A2 (en) * 2000-08-17 2002-02-28 University Of Sheffield Treatment of hyperproliferative diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166319A (en) * 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
WO2002015920A2 (en) * 2000-08-17 2002-02-28 University Of Sheffield Treatment of hyperproliferative diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERKEK E ET AL: "Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis.", DERMATOLOGY (BASEL, SWITZERLAND) 2000, vol. 201, no. 2, 2000, pages 179 - 181, XP009031636, ISSN: 1018-8665 *
See also references of WO02066022A1 *

Also Published As

Publication number Publication date
EP1363611A1 (de) 2003-11-26
JP2004522770A (ja) 2004-07-29
WO2002066022A1 (en) 2002-08-29
CA2437168A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
EP1463438A4 (de) Endomurale therapie
GB0028429D0 (en) Therapy
GB0118373D0 (en) Novel therapeutic method
EP1459776A4 (de) Spritze
GB0126879D0 (en) Combination therapy
GB0108968D0 (en) Methods
GB0118383D0 (en) Therapeutic methods
HU0103986D0 (en) New compounds with therapeutic effect
GB0126251D0 (en) Methods
GB0120042D0 (en) Methods
GB0111146D0 (en) Methods
GB0101933D0 (en) Therapy
GB0108485D0 (en) Combination therapy
GB0116249D0 (en) Methods
GB0108863D0 (en) Combinational therapy
EP1363611A4 (de) Retinoidbehandlung von hepatitis
GB0128651D0 (en) Syringe
IL147696A0 (en) Combination therapy
GB0104555D0 (en) New Therapeutic method
GB0118549D0 (en) Methods
GB0118611D0 (en) Methods
GB0116076D0 (en) Methods
GB0108821D0 (en) Therapy
GB0108817D0 (en) Therapy
GB0108816D0 (en) Therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030901

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1060306

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20040625

17Q First examination report despatched

Effective date: 20041020

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050303

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1060306

Country of ref document: HK